Seleziona un altro paese
Benvenuti
Per favore, leggi le importanti informazioni riportate di seguito prima di continuare sul nostro sito

Lyxor e Lyxor ETF sono nomi utilizzati da Société Générale per identificare rispettivamente le società  di  Asset  Management Lyxor e i prodotti da loro emessi, promossi e/o gestiti.

 

Société Générale è un istituto di credito di diritto francese  autorizzato e controllato in Francia dall’ Autorité de Controle Prudentiel (www.acp.banque-france.fr ), oltre che dall’ Autorité des Marchés Financiers.   Société Générale è autorizzata ad operare in qualità di istituto di credito ed abilitata ad effettuare tutte le operazioni bancarie, nonché abilitata alla prestazione di tutti i servizi d’investimento ad eccezione del servizio di gestione di Sistema Multilaterale di negoziazione, ai sensi delle disposizioni del Code Monétaire et Financier.

 

Société Générale opera in Italia attraverso la succursale di Milano, con domicilio in Via Olona 2, 20123 Milano, Italia. Per informazioni relative a questo sito web: Numero Verde 800 929300 Email: info@etf.it

 

I Lyxor ETFs presentati sul sito www.ETF.it potrebbero essere soggetti a restrizioni per quanto riguarda certe persone o in certi paesi in base alla legislazione locale applicabile alle suddette persone o nei suddetti paesi. E’ responsabilità del cliente assicurarsi di essere autorizzato ad investire nei Lyxor ETFs presentati in questo sito.

 

Gli investitori UK devono fare riferimento a www.lyxoretf.co.uk

Gli investitori Francesi devono fare riferimento a www.lyxoretf.fr

Gli investitori Olandesi devono fare riferimento a www.lyxoretf.nl

Gli investitori Italiani devono fare riferimento a www.lyxoretf.it

Gli investitori Spagnoli devono fare riferimento a www.lyxoretf.es

Gli investitori Austriaci devono fare riferimento a www.lyxoretf.at

Gli investitori Tedeschi devono fare riferimento a www.lyxoretf.de

Gli investitori di Hong Kong devono fare riferimento a www.lyxoretf.hk

Gli investitori Singaporesi devono fare riferimento a www.lyxoretf.sg

Gli investitori Svizzeri devono fare riferimento a www.lyxoretf.ch

Gli investitori Belgi devono fare riferimento a www.lyxoretf.be

 

 

 

 

 

I Lyxor ETFs a cui si fa riferimento in questo sito non sono stati e non saranno registrati sotto il United States Securities Act del 1933 e successive modifiche, e non potranno essere offerti o venduti entro i confini degli Stati Uniti, ad eccezione dei casi di esenzione previsti dal Securities Act, o se nel contesto di una transazione non soggetta agli obblighi di registrazione del Securities Act. Quindi, gli ETF elencati in questo sito internet non potranno essere venduti a cittadini statunitensi o comunque non potranno essere altrimenti trasferiti negli Stati Uniti salvo il caso in cui la transazione di riferimento non sia soggetta ad obblighi di registrazione ai sensi della legge americana.

 

Coloro i quali accedono al sito internet da una giurisdizione nella quale sono vigenti delle restrizioni, dovrebbero informarsi a riguardo, e osservare tali restrizioni.

 

Il presente sito internet non costituisce un offerta o un invito ad acquistare titoli negli Stati Uniti o in qualunque altra giurisdizione in cui simili offerte o inviti non siano autorizzati o a qualunque persona nei confronti della quale sia illegale fare tale offerta o invito. I potenziali utenti del presente sito internet sono invitati a informarsi ed ad osservare tali restrizioni.

 

Questo sito internet ha natura commerciale e non regolamentare. L’accuratezza, la completezza o la rilevanza delle informazioni fornite non è garantita, benchè tali informazioni siano state ricavate da fonti ritenute attendibili. Le informazioni presentate in questo sito internet si basano su dati di mercato in un determinato momento e potrebbero cambiare nel tempo.

 

I Lyxor ETFs descritti nel presente sito non sono adeguati a ogni investiture. L’investitore può perdere fino alla totalità del capitale investito. L’investitore non dovrebbe investire in questi prodotti salvo che ne comprenda pienamente le caratteristiche e il livello di esposizione al rischio. Il valore dei Lyxor ETFs può essere soggetto ad incrementi e riduzioni ed è soggetto a volatilità dovuta a fattori quali variazioni di prezzo degli strumenti sottostanti e dei tassi di interesse. Se il Lyxor ETF è denominato in una valuta diversa dall’indice, è soggetto ad un rischio di cambio.

 

 

 

Prima di ogni investimento in un Lyxor ETF, l’investitore dovrebbe fare la propria valutazione dei rischi dell’investimento sotto il profilo legale, fiscale e contabile, senza fare riferimento alle informazioni fornite in questo sito internet, rivolgendosi, se lo riterrà opportuno, ai propri consulenti specializzati o ad altri professionisti competenti .

Nessuna entità del gruppo Société Générale, potrà essere ritenuta responsabile per le conseguenze finanziarie o di altra natura che potrebbero derivare dall’investimento nei Lxyor ETFs.

 

Prima di ogni eventuale investimento nei Lyxor ETFs si raccomanda di leggere attentamente i Prospetti, i KIID e i Documenti di Quotazione, disponibili sul presente sito e presso Société Générale, Listed Products, via Olona 2, 20123 Milano, in cui sono illustrati in dettaglio i relativi meccanismi di funzionamento, i fattori di rischio ed i costi.

Utilizziamo dei cookies per assicurarci che il nostro sito web funzioni regolarmente e per raccogliere statistiche riguardo agli utenti, così da poter migliorare il sito. Se continuate a visitare il sito, accetterete l’utilizzo dei cookies. Se volete saperne di più, o modificare le vostre impostazioni sui cookies:Clicca qui

Why you should be interested in India

With central banks in retreat across the globe, the dollar weakening and the trade ceasefire holding, emerging market equities are in the spotlight. Chanchal Samadder tells us why India is his market of choice. 

As many an intrepid traveller would tell you, India has a lot to offer. The same is true from an investment perspective. India is the third-largest economy in the world – based on purchasing power parity – at $9.4trn and is the fastest-growing economy among the G20 group of nations. It has also been one of the best-performing equity markets over the past 15 years, having delivered a total return of 10.2% in USD on an annualised basis (vs. 8.1% for emerging markets and 6.7% for developed markets, according to MSCI as at 26/02/2019). Over the last five years, India has outperformed China and the broad MSCI Emerging Markets (EM) Index significantly in USD terms, despite a consistently weakening currency.

In our eyes, there’s more to come. We believe India still offers some of the best return potential among EMs and should have a strategic place in any emerging equity portfolio allocation today. 


Short-term troubles, solid fundamentals

We await the general elections in May 2019 with interest. While policy uncertainty is currently low, some short-term post-election volatility is possible.  There is a chance for change at the top, particularly after the majority party (BJP) lost recent state elections. However, Indian equity return patterns over previous election years show political stability is what matters most, not who wins. They also show that fragmented, unstable coalitions come at a cost.  

For all that, domestic economic conditions are improving. The recovery after the ‘taper tantrum’ lows of 2013 was led by the consumer sector, consumer finance and retail loan-oriented banks but it was impeded by a lack of corporate investment and a sharp rise in stressed assets among financials.

Now though, those financials look far healthier, and the Reserve Bank of India is anticipating fewer non-performing loans for the first time in several years. Domestic consumption is stabilising again, and investment is picking up. Upping the pace of urbanisation should provide another boost. Further progress in capex, credit growth and the end of disinflation means India may well notch up real GDP growth of 7.5-8% over the next five years. 


Capex – the next driver of equity performance

Earnings growth in India averages around 11% over the long term, in line with its long-term nominal GDP growth rate. Shorter-term, the picture is different. Earnings growth has disappointed for a decade, dragged down by indisciplined financials and their bad loan books. Greater regulatory demands on the subsequent balance sheet clean-up were also to blame.

Fast forward to today and the picture is far rosier.  Corporate earnings growth is back above long-term averages and we expect to see further profit normalisation for financials. A pick-up in corporate credit growth, capacity expansion in the materials sector and improved revenues from industrials suggest capex is recovering, which can only be a good thing for equities. The next five years should be more about growth and releveraging, a dual push which, in our view, should keep corporate profitability at or above its long-term average. 


Price to book value vs. history                                12 months fwd EPS growth vs. history 

Chart 1

Sources: Refinitiv, MSCI, Lyxor AM International, data as at 31/01/2019. past performance is no guarantee of future returns 

The dominance of the domestic

Indian households have shown much greater appetite for their stock markets over the last five years, thanks to a series of government measures. These inflows have been a source of real support for the equity market. It has helped reduce volatility, lessen sensitivity with other emerging markets and dampen drawdowns when foreign assets are flowing outwards.

Speaking of domesticity, India is less dependent on exports than China. It relies far more on its internal growth engine, which could insulate it should trade hostilities resume. As we see it, this new version of the Great Game hasn’t played out yet.


At the core of every EM portfolio

Over the past five years, Indian equities have become less volatile due to greater domestic investor participation, lower inflation and less exposure to currency gyrations. The country is not completely insulated from the general sentiment on EMs, but its market beta has declined considerably. While it’s true Indian equities are still trading at premium compared to other EMs, we’d argue these levels are supported by the return to strong EPS growth after that decade in the doldrums.

There’s little doubt in my mind that Indian equities have their place as a core holding in EM portfolios. With a weight of only 8.5% weight in the bellwether MSCI Emerging Markets benchmark, India is under represented in broad EM indices. Our analysis shows that adding a 20% overweight to India to a portfolio tracking the MSCI benchmark improved overall returns and reduced risk over five years. According to our calculations, the annualised volatility of such a portfolio would have been around 5% lower than MSCI EM, while annualised returns were just over 24% higher. 


Performance                                                      Historical volatility

80% MSCI EM +20% MSCI India vs. MSCI         EM  80% MSCI EM+20% MSCI India vs. MSCI

Base 100= 31/12/2 

Chart 2

Source: MSCI, Bloomberg, Lyxor International AM, data as at 25/02/2019

Volatility calculated on 90 days daily returns, *sample period 31/12/2003 to 25/02/2019. Past performance is no guarantee of future returns  


If like us, you believe India should have a greater weight in EM equity allocations, why not consider our MSCI India ETF? It is the best-performing ETF in this universe and comes with the lowest tracking error in Europe.

Find out more about our Lyxor MSCI India UCITS ETF

All views & opinions: Lyxor ETF Equity strategy teams, as at 01 March 2019 unless otherwise stated. These teams are part of Lyxor International Asset Management.


Risk Warning​

This document is for the exclusive use of investors acting on their own account and categorised either as “Eligible Counterparties” or “Professional Clients” within the meaning of Markets in Financial Instruments Directive 2014/65/EU. These products comply with the UCITS Directive (2009/65/EC). Société Générale and Lyxor International Asset Management (LIAM) recommend that investors read carefully the “investment risks” section of the product’s documentation (prospectus and KIID). The prospectus and KIID are available free of charge on www.lyxoretf.com, and upon request to client-services-etf@lyxor.com.

Except for the United-Kingdom, where this communication is issued in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658, this communication is issued by Lyxor International Asset Management (LIAM), a French management company authorized by the Autorité des marchés financiers and placed under the regulations of the UCITS (2014/91/EU) and AIFM (2011/61/EU) Directives. Société Générale is a French credit institution (bank) authorised by the Autorité de contrôle prudentiel et de résolution (the French Prudential Control Authority).

The products mentioned are the object of market-making contracts, the purpose of which is to ensure the liquidity of the products on the London Stock Exchange, assuming normal market conditions and normally functioning computer systems. Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them. Updated composition of the product’s investment portfolio is available on www.lyxoretf.com. In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product, and might also be mentioned on the websites of the stock exchanges where the product is listed.

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice. It is each investor’s responsibility to ascertain that it is authorised to subscribe, or invest into this product. This document is of a commercial nature and not of a regulatory nature. This material is of a commercial nature and not a regulatory nature. This document does not constitute an offer, or an invitation to make an offer, from Société Générale, Lyxor Asset Management (together with its affiliates, Lyxor AM) or any of their respective subsidiaries to purchase or sell the product referred to herein.

Research disclaimer

Lyxor International Asset Management (“LIAM”) or its employees may have or maintain business relationships with companies covered in its research reports. As a result, investors should be aware that LIAM and its employees may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see appendix at the end of this report for the analyst(s) certification(s), important disclosures and disclaimers. Alternatively, visit our global research disclosure website www.lyxoretf.com/compliance.

Conflicts of interest 

This research contains the views, opinions and recommendations of Lyxor International Asset Management (“LIAM”) Cross Asset and ETF research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental Cross Asset and ETF Research opinions and recommendations contained in Cross Asset and ETF Research sector or company research reports and from the views and opinions of other departments of LIAM and its affiliates. Lyxor Cross Asset and ETF research analysts and/or strategists routinely consult with LIAM sales and portfolio management personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of ETFs tracking equity, fixed income and commodity indices. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. Lyxor has mandatory research policies and procedures that are reasonably designed to (i) ensure that purported facts in research reports are based on reliable information and (ii) to prevent improper selective or tiered dissemination of research reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, competitive factors and LIAM’s total revenues including revenues from management fees and investment advisory fees and distribution fees.

Connect with us on linkedin